News | July 16, 2014

Three-year Outcomes for the AF Convergent Procedure Presented at Atrial Fibrillation Symposium

University Medical Center Ljubljana reports longest convergent procedure follow-up to date at the Atrial Fibrillation Symposium 19th Annual Meeting

July 16, 14 — A new physician poster presentation at the Atrial Fibrillation Symposium 19th Annual International Meeting in Orlando, Fla., reports long-term outcomes for the convergent procedure, a multidisciplinary epicardial-endocardial approach to treat patients with persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, recently estimated to affect 33.5 million people worldwide, with a majority of patients falling into the difficult-to-treat persistent AF population.

In this presentation from the University Medical Center Ljubljana in Ljubljana, Slovenia, 76 patients with persistent and longstanding persistent AF were evaluated through continuous loop recorders. At 36 months' follow-up, 84% of patients were in sinus rhythm and only 10% of patients required repeat ablations.

"We continue to see the positive clinical impact of the Convergent Procedure in our persistent AF patients with this three-year data," said Professor Borut Gersak, M.D., Ph.D., of University Medical Center Ljubljana in Ljubljana, Slovenia. "The Convergent Procedure should be a first-line treatment for persistent AF patients. Our long-term results are aligned with other recent publications in the U.S., and we see high single-procedure efficacy compared to endocardial catheter ablation."

The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions created by an electrophysiologist help confirm lesion set completeness through specialized EP diagnostics, which also predict outcomes.

For more informationon: www.ncontactinc.com


Related Content

News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
News

Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...

Home October 13, 2025
Home
News

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure ...

Home September 05, 2025
Home
News

Sept. 3, 2025 — Kardium Inc. recently announced it has received pre-market approval (PMA) for the Globe Pulsed Field ...

Home September 03, 2025
Home
News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
News

July 7, 2025 — Catheter ablation is a minimally invasive treatment for abnormal heart rhythms. It is often successful in ...

Home July 09, 2025
Home
News

June 4, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home June 04, 2025
Home
Subscribe Now